Rog is the Hindi noun meaning ‘disease’. The addition of the prefix ‘a’ changes it to ‘without disease’ a fitting name for our company aiming to bring cures to cancers with a high unmet need.
AROG Pharmaceuticals is a privately held, late-stage biopharmaceutical company. At AROG Pharmaceuticals we are focused on developing treatments for people with cancer where there have been little to no advances in the last 20 years.
AROG Pharmaceuticals is based in Dallas, Texas, and was founded on March 29, 2010. We base our approach on two principles: improving the lives of cancer patients and focusing on indications with high unmet need.
Arog obtained exclusive worldwide rights to several patented benzimidazole-based compounds from Pfizer in April 2010. AROG pharmaceuticals has conducted several clinical trials with crenolanib in acute myeloid leukemia with FLT3 mutations in newly diagnosed or relapsed/refractory (R/R) patient populations; as well as a variety of solid tumors including R/R gastric cancer, gastrointestinal stromal tumors (GIST), and glioblastoma.